PFIZER INC
Ticker: PFEHealthcarePharmaceutical PreparationsS&P 500The business
Pfizer Inc. (NYSE: PFE) is a research-based global biopharmaceutical company headquartered in New York and operates through its website at www.pfizer.com. The company applies science and global resources to discover, develop, manufacture, market, sell and distribute biopharmaceutical products worldwide, focusing on extending and significantly improving patients' lives through medicines and vaccines that address major diseases.
The company operates through three primary divisions within its Biopharma reportable segment, which represents the only reportable segment. The Pfizer U.S. Commercial Division commercializes the entire product portfolio in the United States. The Pfizer International Commercial Division handles commercialization across all international markets. The Global Hospital and Biosimilars organization manages off-patent branded and generic sterile injectables and biosimilars. Additionally, Pfizer operates PC1, a contract development and manufacturing organization supplying specialty active pharmaceutical ingredients, and Pfizer Ignite, which provides R&D services to biotech companies, though the company decided to discontinue Ignite in 2025.
Pfizer's product portfolio spans four primary therapeutic areas: oncology, internal medicine including cardiometabolic and weight management treatments, vaccines for infectious diseases, and inflammation and immunology. Major brands include Comirnaty (COVID-19 vaccine developed with BioNTech), Paxlovid (COVID-19 treatment), Eliquis (anticoagulant), Prevnar family (pneumococcal vaccines), Xtandi (prostate cancer treatment), Ibrance (breast cancer treatment), and the Vyndaqel family (amyloidosis treatment). The company also maintains collaboration and co-promotion agreements with partners including BioNTech, Bristol-Myers Squibb, and Astellas for various products.
The company's R&D operations are managed through a single global organization focused on discovering and developing highly differentiated medicines and vaccines. As of early 2026, Pfizer maintained numerous projects in various development stages across its therapeutic focus areas. The company pursues business development through acquisitions, in-licensing agreements, and strategic partnerships to enhance its pipeline and capabilities. Recent significant transactions include the November 2025 acquisition of Metsera and the December 2023 acquisition of Seagen, along with in-licensing agreements with YaoPharma and 3SBio in obesity, cardiometabolic diseases, and oncology.
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- HQ
- NEW YORK, NY
- FY end
- 12-31
- CIK
- 78003
- SIC
- 2834
Ownership
Who holds PFIZER INC — across funds, superinvestors and bonds · N-PORT 2026Q2 · 13F 2026-06-30
Top fund holders
| Fund | % of fund | Value |
|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VTI · VANGUARD INDEX FUNDS | 0.19% | $4.36B |
| VANGUARD 500 INDEX FUND VOO · VANGUARD INDEX FUNDS | 0.21% | $3.56B |
| Fidelity 500 Index Fund FXAIX · Fidelity Concord Street Trust | 0.23% | $1.90B |
| iShares Core S&P 500 ETF IVV · iShares Trust | 0.21% | $1.89B |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust SPY | 0.21% | $1.66B |
Superinvestors in PFIZER INC
Share of each manager's reported 13F portfolio.
Bonds held by funds
Funds report holding 38 issues of PFIZER INC's debt, $6.49B at fund-held market value — what funds hold, not the company's debt outstanding. Weighted-average coupon 4.47%, maturing 2026–2065.
| Issue | Coupon | Matures | Funds | Fund-held |
|---|---|---|---|---|
| Pfizer Investment Enterprises Pte. Ltd. | 4.750% | 2033-05-19 | 146 | $829.49M |
| Pfizer Investment Enterprises Pte Ltd | 4.450% | 2028-05-19 | 102 | $803.05M |
| Pfizer Investment Enterprises Pte. Ltd. | 5.300% | 2053-05-19 | 143 | $674.59M |
| PFIZER INVSTMNT | 5.110% | 2043-05-19 | 86 | $379.16M |
| Pfizer Investment Enterprises Pte. Ltd. | 5.340% | 2063-05-19 | 113 | $340.72M |
| Pfizer Inc | 4.500% | 2032-11-15 | 65 | $321.31M |
| Pfizer Investment Enterprises Pte Ltd | 4.650% | 2030-05-19 | 76 | $302.33M |
| PFIZER INC | 4.200% | 2030-11-15 | 90 | $289.95M |
| Pfizer Inc | 3.450% | 2029-03-15 | 57 | $273.06M |
| PFIZER INC | 4.875% | 2035-11-15 | 63 | $265.49M |
The 10 largest by fund-held value, of 38.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Go deeper in your own AI
15 years of statements, narrative and filings — queryable over MCP.
Professionals can also use the built-in AI chat (subscription + your own Anthropic key).
15 years of PFIZER INC's financials
Income statement, balance sheet and cash flow across 15 years, every filing with its disclosures, and each number traceable to the filing it came from — free with an account, no card required.
Sign in free